ORKA

Business Context and Reporting Period

Company: Hyseq Pharmaceuticals, Inc. (d/b/a Hyseq, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2002
Business Overview: Hyseq is a biopharmaceutical company focused on discovering and developing therapeutic protein-based products. The company operates two primary segments: Hyseq Pharmaceuticals (therapeutics) and Callida Genomics, Inc. (a majority-owned subsidiary developing sequencing-by-hybridization technology). Key activities include the Phase I clinical trials of alfimeprase (a thrombolytic agent) in collaboration with Amgen, Inc., and agricultural gene discovery collaborations with BASF Plant Science.

Key Financial Metrics

Liquidity and Debt: As of June 30, 2002, the company held $11.8 million in cash and $1.6 million in restricted cash. Current liabilities totaled $18.1 million, including a $4.0 million drawdown on a line of credit from the Chairman and a $4.0 million note payable to Affymetrix. Total liabilities were $23.8 million.

Material Changes vs. Prior Period

• Revenue Growth: Contract revenues increased slightly to $11.9 million for the six months ended June 30, 2002, compared to $11.6 million in the prior year period. This includes amortization of license fees from Affymetrix and upfront payments from Agilent Technologies and Intel Corporation.
• Increased Operating Loss: The net loss for the six months ended June 30, 2002, widened significantly to $27.0 million from $15.1 million in the prior year. This was primarily driven by a $10.0 million non-cash charge recorded in the first quarter for the fair value of warrants granted to Amgen, Inc. under a new collaboration agreement.
• Restructuring Costs: The company recorded a $0.6 million restructuring charge in the second quarter related to personnel severance costs following a strategic reduction of approximately 76 employees to align with the accelerated completion of the BASF collaboration.
• Capital Raising: In April 2002, the company completed a private placement raising approximately $15.0 million (gross) or $14.3 million (net) through the sale of common stock and warrants, significantly bolstering cash reserves compared to the prior year.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Revenue Decline Expected: Management expects revenues for 2003 to be reduced substantially due to the accelerated completion of the BASF collaboration, with final revenue recognition anticipated by January 31, 2003.
• Increased R&D Costs: Research and development expenses are expected to increase substantially in 2003 and beyond as the company proceeds with Phase II and Phase III clinical trials for alfimeprase. The company estimates R&D costs for alfimeprase to be approximately $3.0 million in 2002.
• Cost Control Measures: To preserve cash, the company has implemented a partial hiring freeze, a freeze on capital expenditures, and a deferral of facilities expansion plans.

Key Risks and Contingencies:

• Financing Needs: The company does not generate sufficient cash from operations to fund its activities and will require substantial additional financing in 2003 to continue clinical trials and operations. Failure to secure funding could force the company to delay or scale back programs.
• Regulatory Uncertainty: There is no assurance that alfimeprase or other product candidates will prove safe and effective in human trials or obtain regulatory approval. Clinical development is costly and time-consuming (often exceeding 5 years and $100 million).
• Collaboration Dependence: The business relies heavily on collaborations (e.g., Amgen, BASF, Affymetrix). Termination or failure of these partners to meet milestones could materially harm the company.
• Stock Price Volatility: The company faces risks related to stock price fluctuations, potential delisting from Nasdaq if market capitalization or equity requirements are not met, and dilution from future equity financings.

Investor Verification Checklist

• Amgen Collaboration Terms: Verify the specific milestones and funding responsibilities under the alfimeprase collaboration, particularly the $10 million non-cash warrant charge and future cost-sharing arrangements.
• BASF Revenue Timeline: Confirm the schedule for the remaining $12.6 million in expected revenue from the accelerated BASF collaboration (due Sept 2002, Dec 2002, and Jan 2003).
• Cash Burn Rate: Assess the adequacy of the $11.8 million cash balance against the projected $3.0 million alfimeprase R&D spend for 2002 and the anticipated need for additional funding in 2003.
• Debt Covenants: Review the terms of the $4.0 million Affymetrix note and the Chairman's line of credit, specifically regarding conversion rights and acceleration triggers based on market capitalization.
• Callida Genomics Viability: Evaluate the financial health and funding status of the Callida subsidiary, which operates as a separate segment with its own funding requirements.